RADNOR, Pa., May 19, 2021 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. Michael Stubblefield, President and CEO at Avantor, will represent Avantor in the segment beginning at approximately 9:40 a.m. Eastern Daylight Time.
A live webcast may be accessed through the investor relations section of Avantor’s website at https://ir.avantorsciences.com/investors/news-and-events/ and will be available for replay through June 30, 2021.
About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com.
Media Contact
Allison Hosak
Senior Vice President, Global Communications and Brand
Avantor
908-329-7281
Allison.Hosak@Avantorsciences.com
Investor Relations Contact
Tommy J. Thomas, CPA
Vice President, Investor Relations
Avantor
781-375-8051
Tommy.Thomas@Avantorsciences.com
View original content:http://www.prnewswire.com/news-releases/avantor-to-present-at-goldman-sachs-42nd-annual-global-healthcare-conference-301295213.html
SOURCE Avantor and Financial News
North Bergen, New Jersey--(Newsfile Corp. - July 3, 2025) - Apollo Biowellness, Inc. (OTC Pink:…
AI Code of Conduct’s six core principles key to ensuring the safe and effective use…
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0)…
The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in…
DELRAY BEACH, Fla., July 03, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS)…
DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- The Crosetto Foundation for the Reduction of Cancer…